Advertisement

Journal of Bone and Mineral Metabolism

, Volume 37, Issue 1, pp 105–117 | Cite as

Differential osteopontin expression in human osteoblasts derived from iliac crest and alveolar bone and its role in early stages of angiogenesis

  • Martin Wein
  • Diana Huelter-Hassler
  • Katja Nelson
  • Tobias Fretwurst
  • Susanne Nahles
  • Guenter Finkenzeller
  • Brigitte Altmann
  • Thorsten SteinbergEmail author
Original Article

Abstract

In our previous study, we revealed significant differences of osteopontin (OPN) gene expression in primary human osteoblasts (HOBs) derived from iliac crest bone (iHOBs) and alveolar bone (aHOBs). The present study aims at assigning this discriminative expression to a possible biologic function. OPN is known to be involved in several pathologic and physiologic processes, among others angiogenesis. Therefore, we studied the reaction of human umbilical vein endothelial cells (HUVECs) to HOB-derived OPN regarding angiogenesis. To this end, human primary explant cultures of both bone entities from ten donors were established. Subsequent transcription analysis detected higher gene expression of OPN in iHOBs compared to aHOBs, thereby confirming the results of our previous study. This difference was particularly apparent when cultures were derived from female donors. Hence, OPN protein expression as well as the angiogenic potential of OPN was analyzed, originating from HOBs of one female donor. In accordance to the gene expression level, secreted OPN was more abundant in the supernatant of iHOBs than in aHOBs. Moreover, secreted OPN was found to stimulate migration of HUVECs, but not proliferation or tube formation. These results indicate an involvement in very early stages of angiogenesis and a functional distinction of OPN from HOBs derived from different bone entities.

Keywords

Alveolar osteoblast Iliac crest osteoblast Osteopontin Angiogenesis Human umbilical vein endothelial cells 

Notes

Acknowledgements

We thank Thomas Boschet for the excellent preparation of and technical assistance with the examined HUVECs. Additionally, we thank Balder Rebmann for his expertise and support in conducting the conventional PCR analysis. Further thanks go to Pascal Tomakidi for his support with data interpretation and advice on bone physiology.

Author contributions

MW conducted the experiments, collected the data, and performed the data analysis and writing. He is further responsible for the integrity of the data. DHH contributed to the conduction of the WB experiments, analysis and writing. GF supplied the HUVEC cells for the study. KN, TF and SN provided the bone debris of the alveolar bone and iliac crest and contributed constructive scientific ideas. BA and TS generated the hypothesis, supervised the experimental part and contributed with intellectual input and writing.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights statement

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Bouleftour W, Juignet L, Bouet G, Granito RN, Vanden-Bossche A, Laroche N, Aubin JE, Lafage-Proust MH, Vico L, Malaval L (2016) The role of the SIBLING, Bone Sialoprotein in skeletal biology—contribution of mouse experimental genetics. Matrix Biol 52–54:60–77CrossRefGoogle Scholar
  2. 2.
    Kahles F, Findeisen HM, Bruemmer D (2014) Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab 3:384–393CrossRefGoogle Scholar
  3. 3.
    Kunii Y, Niwa S, Hagiwara Y, Maeda M, Seitoh T, Suzuki T (2009) The immunohistochemical expression profile of osteopontin in normal human tissues using two site-specific antibodies reveals a wide distribution of positive cells and extensive expression in the central and peripheral nervous systems. Med Mol Morphol 42:155–161CrossRefGoogle Scholar
  4. 4.
    Franzen A, Heinegard D (1985) Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J 232:715–724CrossRefGoogle Scholar
  5. 5.
    Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y (2009) Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28:3412–3422CrossRefGoogle Scholar
  6. 6.
    Nilsson SK, Johnston HM, Whitty GA, Williams B, Webb RJ, Denhardt DT, Bertoncello I, Bendall LJ, Simmons PJ, Haylock DN (2005) Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 106:1232–1239CrossRefGoogle Scholar
  7. 7.
    Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276:41–44CrossRefGoogle Scholar
  8. 8.
    Geris L, Gerisch A, Sloten JV, Weiner R, Oosterwyck HV (2008) Angiogenesis in bone fracture healing: a bioregulatory model. J Theor Biol 251:137–158CrossRefGoogle Scholar
  9. 9.
    Tahergorabi Z, Khazaei M (2012) A review on angiogenesis and its assays. Iran J Basic Med Sci 15:1110–1126Google Scholar
  10. 10.
    Percival CJ, Richtsmeier JT (2013) Angiogenesis and intramembranous osteogenesis. Dev Dyn 242:909–922CrossRefGoogle Scholar
  11. 11.
    Goodwin AM (2007) In vitro assays of angiogenesis for assessment of angiogenic and anti-angiogenic agents. Microvasc Res 74:172–183CrossRefGoogle Scholar
  12. 12.
    Poggio P, Grau JB, Field BC, Sainger R, Seefried WF, Rizzolio F, Ferrari G (2011) Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J Cell Physiol 226:2139–2149CrossRefGoogle Scholar
  13. 13.
    Hahnel A, Wichmann H, Greither T, Kappler M, Wurl P, Kotzsch M, Taubert H, Vordermark D, Bache M (2012) Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC Cancer 12:131CrossRefGoogle Scholar
  14. 14.
    Inoue M, Shinohara ML (2011) Intracellular osteopontin (iOPN) and immunity. Immunol Res 49:160–172CrossRefGoogle Scholar
  15. 15.
    Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2011) Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 5:111–122CrossRefGoogle Scholar
  16. 16.
    He B, Mirza M, Weber GF (2006) An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192–2202CrossRefGoogle Scholar
  17. 17.
    Wein M, Fretwurst T, Nahles S, Duttenhoefer F, Tomakidi P, Steinberg T, Nelson K (2015) Pilot investigation of the molecular discrimination of human osteoblasts from different bone entities. J Craniomaxillofac Surg 43:1487–1493CrossRefGoogle Scholar
  18. 18.
    Lee JT, Choi SY, Kim HL, Kim JY, Lee HJ, Kwon TG (2015) Comparison of gene expression between mandibular and iliac bone-derived cells. Clin Oral Investig 19:1223–1233CrossRefGoogle Scholar
  19. 19.
    Long F (2012) Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 13:27–38CrossRefGoogle Scholar
  20. 20.
    Chung IH, Yamaza T, Zhao H, Choung PH, Shi S, Chai Y (2009) Stem cell property of postmigratory cranial neural crest cells and their utility in alveolar bone regeneration and tooth development. Stem Cells 27:866–877CrossRefGoogle Scholar
  21. 21.
    Leucht P, Kim JB, Amasha R, James AW, Girod S, Helms JA (2008) Embryonic origin and Hox status determine progenitor cell fate during adult bone regeneration. Development 135:2845–2854CrossRefGoogle Scholar
  22. 22.
    Zhao H, Feng J, Ho TV, Grimes W, Urata M, Chai Y (2015) The suture provides a niche for mesenchymal stem cells of craniofacial bones. Nat Cell Biol 17:386–396CrossRefGoogle Scholar
  23. 23.
    Matsuura T, Tokutomi K, Sasaki M, Katafuchi M, Mizumachi E, Sato H (2014) Distinct characteristics of mandibular bone collagen relative to long bone collagen: relevance to clinical dentistry. Biomed Res Int 2014:769414Google Scholar
  24. 24.
    Kasperk C, Wergedal J, Strong D, Farley J, Wangerin K, Gropp H, Ziegler R, Baylink DJ (1995) Human bone cell phenotypes differ depending on their skeletal site of origin. J Clin Endocrinol Metab 80:2511–2517Google Scholar
  25. 25.
    Akintoye SO, Lam T, Shi S, Brahim J, Collins MT, Robey PG (2006) Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768CrossRefGoogle Scholar
  26. 26.
    Cheng SL, Zhang SF, Avioli LV (1996) Expression of bone matrix proteins during dexamethasone-induced mineralization of human bone marrow stromal cells. J Cell Biochem 61:182–193CrossRefGoogle Scholar
  27. 27.
    Eijken M, Koedam M, van Driel M, Buurman CJ, Pols HA, van Leeuwen JP (2006) The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 248:87–93CrossRefGoogle Scholar
  28. 28.
    Lee E, Fertig EJ, Jin K, Sukumar S, Pandey NB, Popel AS (2014) Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis. Nat Commun 5:4715CrossRefGoogle Scholar
  29. 29.
    Hakimzadeh N, Stewart DJ, Courtman DW (2010) The role of transglutaminase 2 and osteopontin in matrix protein supplemented microencapsulation of marrow stromal cells. Biomaterials 31:9256–9265CrossRefGoogle Scholar
  30. 30.
    Tang X, Li J, Yu B, Su L, Yu Y, Yan M, Liu B, Zhu Z (2013) Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer. Int J Biol Sci 9:55–66CrossRefGoogle Scholar
  31. 31.
    Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, Wu H, Pritchard C, Nelson PS, Roy-Burman P (2006) Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res 66:883–888CrossRefGoogle Scholar
  32. 32.
    Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, Liu N, Fu Z, Kang C, Pu P, You Y (2010) Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol 12:765–775CrossRefGoogle Scholar
  33. 33.
    Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW (2007) An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26:6361–6371CrossRefGoogle Scholar
  34. 34.
    Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefGoogle Scholar
  35. 35.
    Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401–1409CrossRefGoogle Scholar
  36. 36.
    Nishimichi N, Hayashita-Kinoh H, Chen C, Matsuda H, Sheppard D, Yokosaki Y (2011) Osteopontin undergoes polymerization in vivo and gains chemotactic activity for neutrophils mediated by integrin alpha9beta1. J Biol Chem 286:11170–11178CrossRefGoogle Scholar
  37. 37.
    Nishimichi N, Higashikawa F, Kinoh HH, Tateishi Y, Matsuda H, Yokosaki Y (2009) Polymeric osteopontin employs integrin alpha9beta1 as a receptor and attracts neutrophils by presenting a de novo binding site. J Biol Chem 284:14769–14776CrossRefGoogle Scholar
  38. 38.
    Christensen B, Zachariae ED, Scavenius C, Thybo M, Callesen MM, Kloverpris S, Oxvig C, Enghild JJ, Sorensen ES (2014) Identification of transglutaminase reactive residues in human osteopontin and their role in polymerization. PLoS ONE 9:e113650CrossRefGoogle Scholar
  39. 39.
    Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P et al (2014) Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 18:883–895CrossRefGoogle Scholar
  40. 40.
    O’Loughlin A, Kulkarni M, Vaughan EE, Creane M, Liew A, Dockery P, Pandit A, O’Brien T (2013) Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold enhance wound healing in the alloxan-induced diabetic rabbit ear ulcer model. Stem Cell Res Ther 4:158CrossRefGoogle Scholar
  41. 41.
    Lamalice L, Le Boeuf F, Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100:782–794CrossRefGoogle Scholar
  42. 42.
    Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe Y, Takahashi K, Fukuchi Y, Saijo N, Nishio K (2002) Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98:707–712CrossRefGoogle Scholar
  43. 43.
    Higashikawa F, Eboshida A, Yokosaki Y (2007) Enhanced biological activity of polymeric osteopontin. FEBS Lett 581:2697–2701CrossRefGoogle Scholar
  44. 44.
    Zhang Z, Song Y, Zhang X, Tang J, Chen J, Chen Y (2003) Msx1/Bmp4 genetic pathway regulates mammalian alveolar bone formation via induction of Dlx5 and Cbfa1. Mech Dev 120:1469–1479CrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Martin Wein
    • 1
    • 2
  • Diana Huelter-Hassler
    • 2
    • 3
  • Katja Nelson
    • 4
  • Tobias Fretwurst
    • 4
  • Susanne Nahles
    • 5
  • Guenter Finkenzeller
    • 6
  • Brigitte Altmann
    • 4
  • Thorsten Steinberg
    • 1
    Email author
  1. 1.Department of Oral Biotechnology, University Medical Center Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany
  2. 2.Faculty of BiologyUniversity of FreiburgFreiburgGermany
  3. 3.Department of Orthodontics, Medical Center, University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany
  4. 4.G.E.R.N. Tissue Replacement, Regeneration and Neogenesis, Department of Oral and Maxillofacial Surgery, Medical Center, University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany
  5. 5.Department of Oral- and Maxillofacial SurgeryCharité Campus VirchowBerlinGermany
  6. 6.Department of Plastic and Hand Surgery, Medical Center, University of Freiburg, Faculty of MedicineUniversity of FreiburgFreiburgGermany

Personalised recommendations